|
Symbicort® (budesonide/formoterol) is a treatment for asthma and COPD.
Combining the anti-inflammatory corticosteroid budesonide and the
rapid and long-lasting bronchodilator formoterol in the same inhaler,
providing a simple, convenient and effective treatment.
Prescribing information varies from country to country, so please
consult your local prescribing information.
Asthma:
Symbicort (budesonide/formoterol) SMART® is a new treatment approach for asthma. Symbicort SMART is Symbicort used for both maintenance and relief. With Symbicort SMART, the underlying inflammation is treated with every inhalation of both maintenance and reliever therapy, making it a more effective treatment approach than traditional gold standard therapy, improving daily symptom control and reducing asthma attacks. It is also a simpler regimen since a separate short-acting bronchodilator is no longer needed.
With Symbicort SMART, patients take a maintenance dose of Symbicort in line with normal practice to establish asthma control and take additional inhalations ‘as needed' of Symbicort if symptoms occur, to provide both rapid symptom relief and increased asthma control.
Symbicort SMART may be prescribed for adult patients suitable for combination treatment. However, Symbicort SMART is not licensed for use in children (6-11 years of age) or adolescents (12-17 years of age).
Children and adolescents can be prescribed Symbicort just as before.
COPD:
Symbicort is a maintenance treatment for patients with severe chronic
obstructive pulmonary disease (COPD), FEV1 < 50% predicted, and
a history of repeated exacerbations who cannot be controlled using
long-acting bronchodilators alone.
COPD patients treated with Symbicort have a substantially reduced risk
of exacerbations and an improved quality of life, with increased
confidence to undertake everyday activities that they used to do before
they developed COPD.
Symbicort is the only combination inhaler to show superior benefits to
LABA in reducing exacerbations requiring medical intervention, and to
ICS in reducing exacerbations requiring oral steroid treatment.
| 
